Administrative Core

位于西奈山的照亮可药物基因组的知识管理中心(KMC-IDG)将收集、组织和可视化从以下四个家族收集的数据：蛋白激酶、核受体、离子通道和GPCRs。KMC-IDG还将尝试将这些研究不足的可用药靶点联系起来，用于各种疾病的潜在应用。为了实现这一点，我们将从四个领域收集和提取数据：蛋白质/基因/靶点、药物/干扰物、疾病/表型/副作用以及来自个别患者的数据。将建立各种管道和工作流程，将来自各种疾病的患者集群与研究不足的可用药目标连接起来。Ma‘ayan和Dudley实验室基于他们以前的生产力记录、已经收集和组织的源代码和数据的基础，以及可以定向到新开发的门户网站的强大现有用户基础，处于有利地位，能够成功地开展这一项目。此外，这两个实验室都有很好的合作记录，包括至少一个正在研究中的蛋白激酶作为减轻肾脏纤维化的潜在重要靶点的计算识别和实验验证。这个项目的一个独特和创新的研究部分是对分子和细胞生物学研究领域中存在的文献和实验偏见的来源进行调查。

The Knowledge Management Center for Illuminating the Druggable Genome (KMC-IDG) at Mount Sinai will assemble, organize and visualize data collected from the under-studied druggable genome from the four families: protein kinases, nuclear receptor, ion channels and GPCRs. The KMC-IDG will also attempt linking such under-studied druggable targets for their potential applications in various diseases. To achieve this we will assemble and abstract data from four domains: proteins/genes/targets, drugs/perturbagens, diseases/phenotypes/side-effects, and data from individual patients. Various pipe-lines and workflow will be established to connect clusters of patients from various diseases to under-studied druggable targets. The Ma'ayan and Dudley Labs are well positioned to carry out successfully this project based on their prior track record of productivity, foundation of source code and data that is already collected and organized, and strong existing user base that can be directed to the newly developed portal. In addition, both labs have a strong track record of collaborations including the computational identification and experimental validation of at least one under-studied protein kinase as a potential important target for attenuating kidney fibrosis. One unique and innovative research component of this project is an investigation into the sources of the literature and experimental biases that exist in the molecular and cellular biology research domains.